Autoimmunity After Checkpoint Blockade
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Eligibility criteria
Qualifiers
A diagnosis of cancer and prescription for a checkpoint inhibitor
Disqualifiers
Any subjects not willing or able to give consent
Children under the age of 18
A history of transplant
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov